



Patient Engagement in Clinical Trials

Literature Review – Updated December 2020

A Report of the Science of Patient Input Working Group
of the Medical Device Innovation Consortium (MDIC)

TABLE OF CONTENTS

AUTHORS.....	2
DISCLAIMER.....	3
ABOUT THE MEDICAL DEVICE INNOVATION CONSORTIUM	4
OVERVIEW.....	5
1 ORGANIZATIONAL PATIENT ENGAGEMENT INITIATIVES (ALPHABETICAL ORDER)	6
2 FDA ACTIVITIES, GUIDANCE DOCUMENTS, AND RESOURCES.....	14
3 UNITED STATES-BASED CONFERENCES AND MEETINGS (REVERSE CHRONOLOGICAL ORDER).....	16
4 ENGAGEMENT RESOURCE COMPENDIA (ALPHABETICAL ORDER).....	18
5 SELECTED REFERENCES	20
5.1 Patient Engagement in Clinical Trial Design.....	20
5.2 Patient Engagement in Developing Clinical Outcome Measures	21
5.3 General Patient Engagement in Clinical Research	21
5.4 Patient Preference in Clinical Trial Design	23



AUTHORS

- Wendy Selig, MS, Consultant, WSCollaborative, LLC
- Liliana Rincon-Gonzalez, PhD, Program Director, Science of Patient Input, MDIC

Acknowledgments:

We acknowledge Carrie M Kuehn, M.A., M.P.H., L.P.D, R.A.C for her participation in the 2019 Literature Review from which this was updated.

DISCLAIMER

The views and opinions expressed in this publication are those of the authors and do not necessarily reflect the views and policies of their respective employers; its management, subsidiaries, affiliates, professionals; or any other agency, organization, or company. The views and opinions in this publication are subject to change and revision.

The general recommendations in this document:

- Do not imply FDA concurrence for specific applications
- Do not represent the opinion or policy of the FDA or of the companies represented
- Do not necessarily reflect the official policy or position of MDIC

© Medical Device Innovation Consortium 2021

ABOUT THE MEDICAL DEVICE INNOVATION CONSORTIUM

The Medical Device Innovation Consortium (MDIC) is the first public-private partnership created to advance the medical device regulatory process for patient benefit.

MDIC was formed in 2012 to bring the U.S. Food and Drug Administration (FDA) and industry together to share vital knowledge that can help bring safe, affordable, and effective devices to patients and providers more quickly. MDIC membership and participation is open to nonprofit, industry, and government organizations that are substantially involved in medical device research, development, treatment, or education; or in the promotion of public health; or that have expertise or interest in regulatory science.

MDIC has been designed to pursue several strategies that support its mission:

- Create a forum for collaboration and dialogue
- Make strategic investments in regulatory science, utilizing working groups to identify and prioritize key issues, and to request, evaluate, and implement project proposals
- Provide and enable implementation of tools from these projects that drive cost-effective innovation

The activities and outputs from MDIC are intended to:

- Ensure that innovative technology is readily available to U.S. patients
- Provide industry and government with methods and tools that may be used to expedite medical device development and the regulatory process
- Reduce the risk and expense of clinical research
- Reduce time and cost of medical device development

MDIC members provide guidance and leadership through collaboration to develop solutions for regulatory, scientific, health, and economic challenges within the medical device and diagnostic industry.

MDIC Science of Patient Input (SPI) Program

MDIC's Science of Patient Input (SPI) program provides a venue for continued collaboration to advance the science of patient input in regulatory decision-making, including advances in methodologies, and tactical considerations for integrating the patient's perspective in the design, clinical development, and regulatory review of innovative medical technologies.



OVERVIEW

This document provides an updated Literature Review for the Medical Device Innovation Consortium (MDIC) Science of Patient Input (SPI) Working Group for submission as a deliverable under the MDIC Broad Agency Agreement (BAA) contract.

This high-level review reflects a broad scan of publicly available information about relevant organizations, initiatives, materials, and publications.

While it is up to date as of December 2020, this summary is not exhaustive and should be viewed as a representative snapshot of activities and resources within the highly active and evolving field of patient engagement in clinical research. As new organizations, resources, and publications are being developed and launched continually, this work should be updated regularly to ensure its completeness and relevance over time.

1 ORGANIZATIONAL PATIENT ENGAGEMENT INITIATIVES (ALPHABETICAL ORDER)

Center for Information & Study on Clinical Research Participation (CISCRP)

Center for Information and Study on Clinical Research Participation is an independent, nonprofit organization dedicated to educating patients about clinical research.

Website: <https://www.ciscrp.org/>

Engagement Focus: Clinical Trial Design

Therapeutic Areas: Drugs, Biologics, Devices

Activities: CISCRP is an organization devoted to educating and informing stakeholders in clinical research, including patients, about clinical studies and what it means to be a clinical research participant. CISCRP organizes and facilitates patient panels and advisory boards to address clinical study issues, including patient perceptions on clinical trial design. The organization also conducted a global study on public and patient perceptions of clinical research.

Education Center provides resources for patients about participating in clinical research, including an interactive online community. <https://www.ciscrp.org/education-center/>

CISCRP joined with World Courier to conduct a “Patient Engagement in Clinical Trials” webinar on September 24, 2019. <https://www.ciscrp.org/patient-engagement-in-clinical-trials/>

Clinical Trials Transformation Initiative (CTTI)

CTTI is a public-private partnership to develop and drive adoption of practices that will increase the quality and efficiency of clinical trials.

Website: <https://www.ctti-clinicaltrials.org/>

Engagement Focus: Clinical Trial Design

Therapeutic Areas: Drugs, Biologics, Devices

Activities: CTTI is engaged in multiple activities related to increasing patient engagement in the design and conduct of clinical trials. Recent activities include:

- **Framework for Calculating Value of Patient Engagement** developed by CTTI to estimate net present value of patient engagement in clinical trials. https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/new_ctti_resource_26feb2020_final.pdf
- CTTI cohosted a March 2019 workshop with FDA focused on **Enhancing the Incorporation of Patient Perspectives in Clinical Trials**. <https://www.ctticlinicaltrials.org/news/ctti-and-fda-workshop-will-explore-how-best-include-patientperspectives-clinical-trials/>

- **Clinical Trials Recruitment Planning** initiative led to publication of a proposed framework to enhance trial recruitment strategies, including the central recommendation of engaging the patient as an equal partner in trial planning. <https://www.sciencedirect.com/science/article/pii/S155171441730753X?via%3Dihub/>
- **Digital Health Trials** is an effort to encourage the widespread use of mobile technology in clinical trials. One of the main objectives of this work is the focus on novel endpoints that reflect measures that are meaningful to patients. <https://www.ctti-clinicaltrials.org/programs/mobile-clinical-trials/>
- **Patient Groups & Clinical Trials** is an effort to engage patient groups early and often in the clinical trial process. CTTI has published recommendations for successful collaborations between sponsors and patient groups working on clinical trials. <https://journals.sagepub.com/doi/full/10.1177/2168479017720247/>
- **Financial Value of Patient Engagement** is an effort to provide evidence of value from patient engagement to sponsors conducting clinical trials. This work also resulted in a recent publication. <https://journals.sagepub.com/doi/full/10.1177/2168479017716715/>
- **Effective Engagement with Patient Groups Around Clinical Trials** provides recommendations for trial sponsors (academic and industry) and patient groups to advance collaboration in this area. <https://www.ctti-clinicaltrials.org/files/pgctrecs.pdf>

CTTI's website has a large volume of information and tools for use by sponsors and patient groups interested in engaging patients in all aspects of the clinical trial process, regardless of therapeutic area.

DIA

DIA is a membership organization focused on innovation in life sciences and product development. It was formerly known as the Drug Information Agency, but more recently has expanded its scope of interest to all medical products.

Website: <https://www.diaglobal.org/en/resources/areas-of-interest/patient-engagement/>

Engagement Focus: General Patient Engagement

Therapeutic Areas: Drugs, Biologics, Devices

Activities: DIA has been focused on patient engagement initiatives since 2006, developing resources for the public and its members and focusing on related topics during its meetings.

DIA Patient Engagement Community is an online forum for DIA members, consisting of blog posts, discussion boards, event notifications and other resources. <https://www.diaglobal.org/en/resources/areas-of-interest/patient-engagement>

Study of Patient-Centric Initiatives:

- **Considerations Guide** is a practical resource for companies launching or advancing patient-centered initiatives that support healthcare product research and development. http://engage.diaglobal.org/PatientEngagementConsiderationsGuide.html?_ga=2.233867806.1209464920.1609281055-501829263.1609281055
- **Capturing the Value of Patient Engagement** presents key insights in the following areas: adoption of patient-centric initiatives, barriers to adoption, comparative analytics, and results of patient-centric initiatives.

http://engage.diaglobal.org/DIAPatientEngagementStudy.html?_ga=2.138076019.297563242.1550515532-714288693.1548869872/

DIA-Tufts Center for the Study of Drug Development (CSDD) Patient Engagement Research Project is funded by 17 pharmaceutical companies and contract research organizations. <https://www.diaglobal.org/en/resources/press-releases/2016/10-31-patient-engagement-study/>

FasterCures—A Center of the Milken Institute

FasterCures is a nonprofit think tank focused on cutting through roadblocks that slow medical progress by expanding the science of patient input, fostering policies to support biomedical innovation, and spurring cross-sector collaboration in research to get better outputs.

Website: <https://milkeninstitute.org/centers/fastercures>

Engagement Focus: General Patient Engagement

Therapeutic Areas: Drugs, Biologics, Devices

Activities: FasterCures develops and provides curation for resources for patient advocacy organizations and stakeholders in the medical research ecosystem through its “Engaging Patients in Research” program. <https://milkeninstitute.org/programs/engaging-patients-in-research>

- **Advancing Models of Patient Engagement: Patient Organizations as Research and Data Partners** (October 2020). <https://milkeninstitute.org/reports/advancing-models-patient-engagement-patient-organizations-research-and-data-partners>
- **Patient-Focused Drug Development Meetings: Smart Practices from Community Leaders** (September 2020). <https://milkeninstitute.org/reports/patient-focused-drug-development-meetings-smart-practices-community-leaders>
- **Nonprofits: A Growing Force in Drug Development** (May 2020) <https://milkeninstitute.org/reports/nonprofits-growing-force-drug-development>
- **Patient-Centric Initiatives: Focusing for Impact** (2019) <https://milkeninstitute.org/reports/patient-centric-initiatives-focusing-impact>

Health Technology Assessment International (HTAi)

HTAi is a membership organization focused on the understanding and use of health technology assessment to inform healthcare decision-making and efficient use of healthcare resources.

Website: <https://htai.org/>

Engagement Focus: General Patient Engagement

Therapeutic Areas: Drugs, Biologics, Devices

Activities: The Patient and Citizen Involvement special interest group (PCIG) is focused on obtaining patient perspectives to improve health technology assessment. This group has generated multiple resources for its members relating to patient engagement in HTAi. <https://htai.org/interest-groups/pcig/>

- **HTAi Glossary for Consumers and Patients** is a beginner’s guide to the words used in health technology assessment (HTAi). https://htai.org/wp-content/uploads/2018/02/HTAiPatientAndConsumerGlossaryOctober2009_01.pdf
- **For HTA Agencies and Policy Makers** includes multiple resources to support HTA submissions. <https://htai.org/interest-groups/pcig/resources/for-hta-agencies-and-policymakers/>
- **For Patient Groups and Individual Patients**, <https://htai.org/interestgroups/pcig/resources/for-patients-and-patient-groups/>
- **For Industry and Researchers** includes links to ethical guides and national codes of practice for patient engagement collaborations. <https://htai.org/interestgroups/pcig/resources/for-industry-and-researchers/>
- **PCIG Webinar (2017) to the International Network of Agencies for Health Technology Assessment (INAHTA)** https://www.dropbox.com/s/r6ieika37813w68/INAHTA%20Patient%20Involvement%20Webinar_2017.mp4?dl=0 /

Professional Society for Health Economic and Outcomes Research (ISPOR)

ISPOR is the professional society for health economic and outcomes research (HEOR). ISPOR has a strategic initiative focused on patient engagement in HEOR, including a Patient Representative Roundtable program, which convenes stakeholders with the goal of engaging patient representatives in the research and decision-making processes, and a Patient Centered Special Interest Group, which works to facilitate the involvement of patient representatives in all stages of research and decision-making to improve healthcare and its delivery and outcomes.

Website: <https://www.ispor.org> and <https://www.ispor.org/strategic-initiatives/patient-initiatives>

Engagement Focus: Outcomes Research

Therapeutic Areas: Drugs, Biologics, Devices

Medical Device Innovation Consortium (MDIC)

The Medical Device Innovation Consortium (MDIC) Science of Patient Input (SPI) initiative comprises several projects aimed at enhancing patient engagement in medical device clinical trials and product development efforts. This initiative, previously known as Patient Centered Benefit-Risk, relies on multistakeholder working groups and committees to evaluate the landscape, identify gaps, and generate resources on these topics for the medical device community.

Website: <https://mdic.org/program/science-of-patient-input/>

Engagement Focus: Patient Preference Assessment, Clinical Trial Design

Therapeutic Area: Devices

Activities: MDIC and its partners are collaborating to improve the field’s ability to include patient perspectives in the development, premarket approval, and postmarket evaluation of medical devices. The vision of the MDIC Science of Patient Input Steering Committee is to provide a venue for continued collaboration to advance the art and science of patient engagement in regulatory science, including advances in methodologies and tactical considerations for integrating the patient’s perspective and preferences in the design, clinical development, and regulatory review of innovative medical technologies. The MDIC SPI website includes multiple relevant resources:

- **MDIC’s Patient Input in Clinical Trial Design project** focuses on three workstreams to develop: (1) methodologies to systematically identify outcomes that matter most to patients and establish these

outcomes as primary or secondary endpoints for clinical studies, (2) guidelines to integrate patient preferences into the statistical design of clinical trials, and (3) methodologies to maximize patient participation in clinical trials. <https://mdic.org/project/patient-input-in-clinical-trial-design>

- **MDIC's Patient Centered Benefit-Risk (PCBR) project** launched in 2013 with the vision "to establish a credible framework for assessing patient preferences regarding the probable benefits and risks of a proposed medical device and for incorporating patient preference information into pre-market and post-market regulatory submissions and decisions." This project resulted in publication of "A Framework for Incorporating Information on Patient Preferences Regarding Benefit and Risk into Regulatory Assessments of New Medical Technology" (May 2015). <https://mdic.org/resource/patient-centered-benefit-risk-pcbr-framework/>
- **MDIC's Patient Centered Outcomes Research Project** engaged the Michael J. Fox Foundation for Parkinson's Research (MJFF), CDRH, Massachusetts Institute of Technology (MIT), and RTI Health Solutions to investigate how the preferences of patients with Parkinson's disease (PD) could be used to set statistical significance levels in clinical trial design. <https://mdic.org/project/patient-centered-outcomes-research/>
- **MDIC's Heart Failure Project** engaged six medical device companies supportive of learning more about patient preferences in the treatment of heart failure to develop and conduct a patient preference study aimed at understanding patient preferences for features relevant to various heart failure interventions including effectiveness outcomes. The primary study objective was to apply best-practice stated-preference methods to quantify heart-failure patients' willingness to accept therapeutic risks in exchange for improved effectiveness of devices used to manage heart failure. <https://mdic.org/project/heart-failure-study/>

National Cancer Institute (NCI)

The National Cancer Institute Office of Advocacy Relations links advocate stakeholders with NCI to ensure collective patient perspectives are included in NCI cancer research activities.

Website: <https://www.cancer.gov/about-nci/organization/oar>

Engagement Focus: Clinical Trial Design

Therapeutic Areas: Drugs, Biologics, Devices

Activities: NCI's Office of Advocacy Relations (OAR) is the primary resource at the organization for engaging with the cancer advocacy community. <https://www.cancer.gov/aboutnci/organization/oar/research-advocacy/>

A summary of OAR's engagement activities was presented at the FDA Patient Engagement Advisory Committee (PEAC) meeting in October 2017. Included in these activities are:

- **Clinical Trials and Translational Research Advisory Committee (CTAC)**, an external multistakeholder oversight committee that advises NCI on ways to strengthen its intramural and external research enterprises, leveraging several ad hoc working groups that engage with patient advocates within various high-priority tumor types. <https://www.cancer.gov/about-nci/organization/ccct/ctac/>
- **NCI's Council of Research Advocates (NCRA)**, the only federal advisory committee solely comprises advocate leaders at NCI. NCRA convenes around broad cancer research issues and provides the Director with advice and strategic insights from the community's perspective. <https://www.cancer.gov/about-nci/organization/oar/ncra>

- **NCI's Scientific Steering Committees and Task Forces**, which include patient advocates, guide NCI's clinical trial enterprise.

National Health Council (NHC)

National Health Council (NHC) is an advocacy organization whose mission is to provide a voice for patients with chronic diseases and disabilities as well as their caretakers. NHC is a membership organization with participation from advocacy groups, and industry, payer, and other medical product and healthcare stakeholders.

Website: <https://www.nationalhealthcouncil.org/>

Engagement Focus: General Patient Engagement

Therapeutic Areas: Drugs, Biologics

Activities: One of NHC's public policy areas is patient engagement. Though NHC has participation from all therapeutic areas, including devices, NHC's work in patient engagement in clinical research is limited to drugs and biologics. NHC desires to identify and implement best practices for engaging patients in the research, development, and regulatory review of new drugs. <http://www.nationalhealthcouncil.org/public-policy/patient-engagement/>

In collaboration with the Genetic Alliance, NHC has generated white papers on the topic of patient engagement in clinical research and is working to generate recommended language for use in FDA patient engagement guidance documents.

- **Engagement Toolbox** comprises resources developed by NHC to support patient engagement by medical product developers, including tools to determine appropriate compensation of patients and tools to support contracting (coming soon). <https://nationalhealthcouncil.org/patient-engagement-compensation-and-contracting/>
 - Fair-Market Value Calculator and Engagement Templates
<https://www.nationalhealthcouncil.org/resources/fair-market-value-calculator>
- **Clinical Outcomes Assessment** is an area of current focus for NHC, which has convened several webinars on the topic. <https://www.nationalhealthcouncil.org/publicpolicy/clinical-outcome-assessment/>
- **Sponsor-Patient Interactions During Drug Development** was a multistakeholder 2017 meeting convened to discuss best practices for patient engagement. <https://www.nationalhealthcouncil.org/wp-content/uploads/2019/12/Sponsor-Patient%20Interactions%20during%20Drug%20Development.pdf>

Patient-Centered Outcomes Research Institute (PCORI)

PCORI was established to fund clinical-effectiveness research that can help patients and caregivers make better-informed healthcare decisions. PCORI also funds projects focused on research methods and capacity and works to influence research funded by others to be more useful to patients and other healthcare decision-makers.

Website: <https://www.pcori.org/>

Engagement Focus: Clinical Outcomes Development

Therapeutic Areas: Drugs, Biologics, Devices

Activities: PCORI has supported engagement of multiple stakeholders in clinical research through their "Engagement in Research PCORI" program. Some of these activities include:

PCORI Engagement Resources & Guidance Documents

- **Engagement in Health Research Literature Explorer** is a searchable list of publications on engagement in health research. This resource is sortable by article topic type, types of stakeholders engaged, and phase(s) of research in which engagement occurred, from identifying research questions to sharing study results. Articles are listed if they met PCORI's search and inclusion criteria. <https://www.pcori.org/engagement/engagement-literature>
- **Engagement Plan Template** provides guidance for methods of engaging stakeholder partners throughout each phase of a research study (Updated October 2020). <https://www.pcori.org/sites/default/files/PCORI-Updated-Engagement-Plan-Template.pdf>
- **Engagement Rubric** provides guidance, definitions, and principles for patient engagement in research (developed in 2014 and updated in 2016). <https://www.pcori.org/sites/default/files/Engagement-Rubric.pdf>
- **Compensation Framework** provides guidance for developing fair compensation levels for patients, caregivers, and organizations that participate in research. <https://www.pcori.org/sites/default/files/PCORI-Compensation-Framework-for-EngagedResearch-Partners.pdf/>
- **PCORI Methodology Standards** provide specific benchmarks for researchers across an array of aspects. There are four standards associated with Patient Centeredness, and standard PC-1 focuses specifically on engagement. <https://www.pcori.org/researchresults/about-our-research/research-methodology/pcori-methodologystandards#Associated%20with%20Patient-Centeredness/>
- **Advisory Panel on Patient Engagement** meets regularly to discuss key topics in the field of patient engagement. <https://www.pcori.org/events/2019/advisory-panel-patient-engagement-fall-2019-meeting>
- **Engagement Tool and Resource Repository** is a searchable database of engagement tools and resources used by PCORI awardees. <https://www.pcori.org/engagement/engagement-resources/Engagement-Tool-Resource-Repository>

PCORI Fact sheets

- **Better Research Through Engagement** <https://www.pcori.org/sites/default/files/PCORI-Better-Research-ThroughEngagement.pdf>
- **Engagement Challenges, Strategies, and Resources** <https://www.pcori.org/sites/default/files/PCORI-Patient-Stakeholder-EngagementChallenges-Strategies-Resources-Handout-120517.pdf>
- **Roles of Patient and Stakeholder Partners in Patient-Centered Research** <https://www.pcori.org/sites/default/files/PCORI-Engagement-in-Research-Making-aDifference-Webinar-Info-Sheet-091917.pdf>
- **Research Done Differently** <https://www.pcori.org/sites/default/files/PCORI-Research-Done-Differently.pdf>
- **Initiating Partnerships for Patient-Centered Research** <https://www.pcori.org/sites/default/files/PCORI-Engagement-Strategies-for-Initiating-Research-Partnerships-Info-Sheet-71917.pdf>

PCORI Webinars Archive

- **Engagement Strategies, Challenges, and Resources** <https://www.pcori.org/events/2017/patient-and-stakeholder-engagement-researchengagement-challenges-strategies-and>

- **Strategies for Initiating Research Partnerships** <https://www.pcori.org/events/2017/patient-and-stakeholder-engagement-researchstrategies-initiating-research-partnerships>
- **Engagement Challenges and Solutions Presentation**, PCORI Annual Meeting (2016)
<https://custom.cvent.com/90B233E1C037437BB4FE6D4881DF9A22/files/0fc56ffc17b445d5bae44c31360b3f73.pdf>

PCORnet Engagement Assessment Report (PCORnet) deals with engagement of patients and stakeholders in research networks rather than individual research studies, but there may be common lessons and challenges about engagement.

<https://www.pcori.org/engagement/engagement-resources/Engagement-Tool-Resource-Repository/engagement-assessment-project>

TransCelerate BioPharma Inc.

TransCelerate BioPharma’s mission is to collaborate across the global biopharmaceutical research and development community to identify, prioritize, design, and facilitate implementation of solutions designed to drive the efficient, effective, and high-quality delivery of new medicines. TransCelerate membership is available to biopharmaceutical research and development organizations that engage in innovative discovery, development, and manufacturing of new drugs. TransCelerate’s growing portfolio of initiatives focuses on the shared vision of accelerating and enhancing the research and development of innovative new therapies. Their initiatives develop practical solutions to overcome inefficiencies in clinical research and are drawn from the combined expertise of members and industry collaborators.

Website: <https://www.transceleratebiopharmainc.com/>

Engagement Focus: Clinical Trial Design, Patient Experience

Therapeutic Area: Drugs

Activities: TransCelerate leverages collaboration among multiple companies to improve clinical trial efficiency and advance drug development. The organization has many activities across multiple areas of focus, including its Patient Experience (PE) Initiative, which seeks to facilitate and accelerate the industry’s progression toward a future where the patient experience is enhanced in clinical trials and patient burden is reduced, and its Patient Technology (PT) Initiative, which seeks to facilitate and accelerate the industry’s progression toward a future where patients have access to innovative technologies that enhance the patient experience and reduce patient burden in clinical trials.

- **Patient Protocol Engagement Toolkit** for trial sponsors.
<https://www.transceleratebiopharmainc.com/ppet/planning-for-patient-engagement/>
- **Patient Experience Initiative** includes multiple resources and solutions aimed at improving the patient experience in clinical research. <https://www.transceleratebiopharmainc.com/initiatives/patient-experience/>
- **Patient Technology Initiative** addressed barriers for patient participation in clinical trials. Published manuscript on accelerating adoption of patient-facing technologies.
<https://journals.sagepub.com/doi/10.1177/2168479018801566> and **Implementation Guide**
<http://www.transceleratebiopharmainc.com/wp-content/uploads/2018/12/PT-Implementation-Framework-v3.6-12.11.18-2.pdf>
<https://www.transceleratebiopharmainc.com/initiatives/patient-technology/>

2 FDA ACTIVITIES, GUIDANCE DOCUMENTS, AND RESOURCES

Patient Engagement Collaborative (PEC), a work group created with CTTI, comprises patient advocacy organizations convened to discuss patient engagement at the FDA.

<https://www.fda.gov/forpatients/patientengagement/default.htm#collaborative>

Patient Participation in Medical Product Discussions (FDASIA Section 1137) recognizes the value of patient input by facilitating increased involvement of patients earlier in the regulatory process for medical product review.

<https://www.fda.gov/forpatients/patientengagement/default.htm#fdasia1137>

Patient Engagement in the Design and Conduct of Medical Device Clinical Investigations. Draft Guidance September 2019.

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/patient-engagement-design-and-conduct-medical-device-clinical-investigations>

Patient Reported Outcomes – Clinical Outcomes Assessment Qualification

<https://www.fda.gov/regulatory-information/search-fda-guidance-documents/requests-feedback-and-meetings-medical-device-submissions-q-submission-program>

- **Guidance for Industry**

<https://www.fda.gov/downloads/drugs/guidances/ucm193282.pdf>

- **Patient-Focused Drug Development (PFDD) CDER Guidance Series**

FDA is developing a series of four methodological patient-focused drug development (PFDD) guidance documents to address, in a stepwise manner, how stakeholders can collect and submit patient experience data and other relevant information from patients and caregivers for medical product development and regulatory decision-making.

This series of guidance documents is intended to facilitate the advancement and use of systematic approaches to collect and use robust and meaningful patient and caregiver input that can better inform medical product development and regulatory decision-making.

These guidances are part of FDA's PFDD efforts in accordance with the 21st Century Cures Act and The Food and Drug Administration Reauthorization Act of 2017 Title I.

<https://www.fda.gov/drugs/developmentapprovalprocess/ucm610279.htm>

- *Guidance 1: Collecting Comprehensive and Representative Input*
- *Guidance 2: Methods to Identify What is Important to Patients*
- *Guidance 3: Selecting, Developing or Modifying Fit-for-Purpose Clinical Outcomes Assessments*
- *Guidance 4: Title forthcoming, will address topics related to COA-related endpoint development and interpretation, including topics related to instrument administration and meaningful within-patient score changes*

- **Plan for Guidance Development**

<https://www.fda.gov/drugs/developmentapprovalprocess/ucm610279.htm>

- **Voice of the Patient Meetings**

<https://www.fda.gov/ForIndustry/UserFees/PrescriptionDrugUserFee/ucm347317.htm>

Center for Devices and Radiological Health (CDRH) Patient Engagement

<https://www.fda.gov/about-fda/center-devices-and-radiological-health/cdrh-patient-engagement>

CDRH Patient Preference Initiative

- **Patient Preference in Medical Device Decision-Making** <https://www.fda.gov/about-fda/cdrh-patient-engagement/patient-preference-information-ppi-medical-device-decision-making>
- **Patient Preference-Sensitive Areas: Using Patient Preference Information in Medical Device Evaluation** <https://www.fda.gov/about-fda/cdrh-patient-engagement/patient-preference-sensitive-areas-using-patient-preference-information-medical-device-evaluation>
- **Patient Perspective Workshop (2013)**
<http://wayback.archiveit.org/7993/20170112084903/http://www.fda.gov/MedicalDevices/NewsEvents/WorkshopsConferences/ucm361864.htm>

CDRH Patient Engagement Advisory Committee (PEAC) provides advice to the Commissioner or designee on complex issues relating to medical devices, the regulation of devices, and their use by patients. The Committee may consider topics such as Agency guidance and policies, clinical trial or registry design, patient preference study design, benefit-risk determinations, device labeling, unmet clinical needs, available alternatives, patient-reported outcomes and device-related quality of life or health status issues, and other patient-related topics.

<https://www.fda.gov/advisorycommittees/committeesmeetingmaterials/patientengagementadvisorycommittee/default.htm>

<https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHPatientEngagement/ucm462829.htm>


- **2020 Meeting Materials:** <https://www.fda.gov/about-fda/cdrh-patient-engagement/cdrh-patient-engagement-advisory-committee>
- **2019 Meeting Materials:** <https://www.fda.gov/advisory-committees/patient-engagement-advisory-committee/september-10-2019-patient-engagement-advisory-committee-meeting-announcement-09102019-09102019>
- **2018 Meeting Materials:**
<https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PatientEngagementAdvisoryCommittee/ucm621264.htm>
- **2017 Meeting Materials:**
<https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PatientEngagementAdvisoryCommittee/ucm578522.htm>

MyStudies App, launched by Center for Drug Evaluation and Research (CDER) to facilitate the input of real-world data directly by patients, can be linked to electronic health data supporting traditional clinical trials, pragmatic trials, observational studies, and registries. <https://www.fda.gov/Drugs/ScienceResearch/ucm624785.htm>

3 UNITED STATES-BASED CONFERENCES AND MEETINGS (REVERSE CHRONOLOGICAL ORDER)

A selection of meetings that occurred or are planned with a specific focus on patient engagement in clinical trials. Materials produced by these meetings are or will be available at the conference websites. Note, it may be necessary to navigate the websites if the desired content is not on the home page.

- MDIC Patient Engagement Forum (November 2020) <https://mdic.org/event/patient-engagement-forum-virtual/>
- ISPOR-FDA Virtual Summit. Using Patient-Preference Information in Medical Device Regulatory Decisions: Benefit-Risk and Beyond (September 2020) <https://www.ispor.org/conferences-education/conferences/past-conferences/ispor-fda-summit-2020>
- NHC Science of Patient Engagement Symposium (September 2020) <https://nationalhealthcouncil.org/2020-science-of-patient-engagement-symposium/>
- CISCRP Patient Engagement in Clinical Trials Webinar (September 2019) <https://www.ciscrp.org/patient-engagement-in-clinical-trials/>
- National Academies of Science (NAS). Advancing the Science of Patient Input in Medical Product R&D Workshop (July 2019) <https://www.nationalacademies.org/event/09-19-2017/advancing-the-science-of-patient-input-in-medical-product-r-d-towards-a-research-agenda-a-workshop>
- CTTI-FDA Patient Engagement Workshop (March 2019) <https://www.ctti-clinicaltrials.org/news/recording-now-available-ctti-and-fda-hold-workshop-incorporating-patient-perspectives-clinical>
- CDRH Patient Engagement Advisory Committee (PEAC) Meeting (November 2018) <https://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/PatientEngagementAdvisoryCommittee/ucm621264.htm>
- DIA Measuring Impact in Patient Centered Drug Development Conference (October 2018) <https://www.diaglobal.org/en/conference-listing/meetings/2018/10/measuring-impact-inpatient-centered-drug-development>
- MDIC Patient Centered Clinical Trials Workshop (May 2018) <https://mdic.org/project/may-18-2018-patient-centered-clinical-trial-design-workshop/>
- Patients as Partners, U.S. (Annual Conference). Conference focuses on involvement of patients throughout the lifecycle of medical products. <https://theconferenceforum.org/conferences/patients-as-partners/overview/>
- CDRH Patient Engagement Advisory Committee (PEAC) Meeting (October 2017). Inaugural PEAC meeting focused on engagement of patients in clinical trials. <https://www.fda.gov/advisorycommittees/calendar/ucm568511.htm>
- University of Maryland M-CERSI Conference on Patient Focused Drug Development (March 2015) <https://www.pharmacy.umaryland.edu/centers/cersievents/patient-focuseddrug-development/>

- 
- **CTTI Patient Groups and Clinical Trials Expert Meeting (January 2015).** Meeting focused on successes, barriers, and the value of patient engagement in clinical trials. <https://www.ctti-clinicaltrials.org/briefing-room/meetings/patient-groups-and-clinical-trials-expert-meeting>

4 ENGAGEMENT RESOURCE COMPENDIA (ALPHABETICAL ORDER)

There are multiple organizations that provide assemblies of information on patient engagement. Each of these “engagement resource compendia” includes large volumes of information:

Alliance for Clinical Research Excellence and Safety (ACRES)

<http://www.acresglobal.net/>

Patient Empowerment Initiative (PEI)

Resource: Collects, synthesizes, and tests best practice methods for engagement in clinical research. Integrate patient centricity efforts across the research and healthcare environment.

Therapeutic Areas: Drugs, Biologics, Devices

Focus: General Patient Engagement

Biotechnology Innovation Organization (BIO)

https://www.bio.org/sites/default/files/legacy/bioorg/docs/BIO_PPMD_Paper_2016.pdf

Key Considerations for Developing and Integrating Patient Perspectives in Drug Development: Examination of the Duchenne Case Study

Resource: Shares best practices for the development of disease-specific patient preference studies based on the joint initiative between Parent Project Muscular Dystrophy (PPMD) and BIO. The paper outlines key considerations to help guide stakeholders on the development of patient preference studies and the multitude of ways they can be used, including to help inform the drug development and regulatory processes.

Therapeutic Areas: Drugs, Biologics

Focus: Benefit Risk, Patient Preferences

MDIC

<https://mdic.org/resource/patient-centered-benefit-risk-pcbr-framework/>

Patient Centered Benefit-Risk (PBCR) Framework

Resource: Provides background on the concepts of benefit-risk and patient preference, discusses the potential value of including patient benefit-risk in a regulatory submission and when in the product lifecycle such information might be collected, outlines factors to consider when selecting a patient preference method, and discusses considerations regarding the use of patient preference information in the regulatory process.

Therapeutic Areas: Devices

Focus: Benefit-Risk, Patient Preferences

Patient Focused Medicines Development

www.patientfocusedmedicine.org

SYNAPSE: Synergizing Patient Engagement

Resource: A registry of patient engagement initiatives across the globe; includes a search engine to identify specific patient engagement efforts

Therapeutic Areas: Drugs, Biologics, Devices

Focus: General Patient Engagement

PCORI

<https://www.pcori.org/literature/engagement-literature/>

Engagement in Health Research Literature Explorer

Resource: Searchable database of publications about engagement in health research, not limited to PCORI studies

Therapeutic Areas: Drugs, Biologics, Devices

Focus: General Patient Engagement, Technology

TransCelerate

<https://www.transceleratebiopharmainc.com/>

Patient Experience Initiative: Enables greater patient engagement and partnership between patients and sponsors to design and execute clinical protocols that create better patient experiences in clinical trials

Patient Technology Initiative: Addresses the barriers to the use of patient-facing technologies (PT) in clinical trials to benefit individual patients and the broader patient community, as well as sponsors, sites, and vendors

The Research Acceleration and Innovation Network (TRAIN)

<https://milkeninstitute.org/centers/fastercures/train>

Resource: A collection of tools, publications, webinars, and events related to patient engagement, including patient input to clinical research

Therapeutic Areas: Drugs, Biologics, Devices

Focus: General Patient Engagement

5 SELECTED REFERENCES

This curated list contains selected references identified through a high-level review of published literature, literature database searches, and citations in other documents. The list is divided into categories of literature pertaining to development of clinical outcomes, clinical trial design, and general patient engagement. These categories are not mutually exclusive; they are intended to provide some guidance as to which articles cover the two specific topic areas of interest. New publications on the topic of patient engagement in research are being disseminated frequently, and this list should be updated regularly.

5.1 Patient Engagement in Clinical Trial Design

AdvaMed. Regulatory Comments Submitted to FDA Docket No. FDA-2014-N-1698. 2014.

Bloom D, Beetsch J, Harker M, et al. The rules of engagement. *Ther Innov Regul Sci*. 2018;52(2):206-213.

Center for Information & Study on Clinical Research Participation. *Perceptions & Insights Study. General Perceptions and Knowledge on Clinical Research*. 2017.

Center for Information & Study on Clinical Research Participation. *Perceptions & Insights Study. The Participation Decision-Making Process*. 2017.

Center for Information & Study on Clinical Research Participation. *Perceptions & Insights Study. The Participation Experience*. 2017.

Cobb EM, Meurer W, Harney D, et al. Patient engagement in neurological clinical trials design: a conference summary. *Clin Transl Sci*. 2015;8(6):776-778.

Clinical Trials Transformation Initiative. CTTI Recommendations. *Effective Engagement with Patient Groups Around Clinical Trials*. 2015.

Evidera. *Are Patients at the Center of Your Trials?* Spring 2019.

Eye For Pharma. Patient-Centered Drug Development. *A Roadmap for Pharmaceutical Leaders*. 2015.

Forsythe L, Heckert A, Margolis MK, Schrandt S, Frank L. Methods and impact of engagement in research, from theory to practice and back again: early findings from the Patient-Centered Outcomes Research Institute. *Qual Life Res*. 2018;27:17.

Forsythe LP, Carman KL, Szydowski V, et al. Patient engagement in research: early findings from the Patient-Centered Outcomes Research Institute. *Health Aff (Millwood)*. 2019;38(3):359-367.

Marsden J, Bradburn J. Patient and clinician collaboration in the design of a national randomized breast cancer trial. *Health Expect*. 2004;7(1):6-17.

O'Daly S, Dowd S, Cassidy N, et al. Incorporating patient input into clinical trials. *Sleep Med*. 2017;40(Suppl 1):e243-e244.

Mullins CD, Vandiago J, Zheng Z, Wicks P. Patient-centeredness in the design of clinical trials. *Value Health*. (2014);17(4):471-475.

5.2 Patient Engagement in Developing Clinical Outcome Measures

Concannon TW, P. Meissner, Grunbaum JA, et al. A new taxonomy for stakeholder engagement in patient-centered outcomes research. *J Gen Intern Med*. 2012;27(8): 985-991.

Frank L, Forsythe L, Ellis L, et al. Conceptual and practical foundations of patient engagement in research at the patient-centered outcomes research institute. *Qual Life Res*. 2015;24(5):1033-1041.

Kirwan JR, de Wit M, Frank L, et al. Emerging guidelines for patient engagement in research. *Value Health*. 2017;20(3):481-486.

Williamson PR, Altman DG, Blazeby JM, et al. Developing core outcome sets for clinical trials: issues to consider. *Trials*. 2012;13(1):132.

5.3 General Patient Engagement in Clinical Research

Anderson M, McCleary KK. On the path to a science of patient input. *Sci Transl Med*. 2016;8(336):336ps311.

Cheung PP, De Wit M, Bingham CO, et al. Recommendations for the involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A report from the OMERACT 2014 Working Group on PRP. *J Rheumatol*. 2016;43(1):187-193.

Dewulf L. Patient engagement by pharma – why and how? A framework for compliant patient engagement. *Ther Innov Regul Sci*. 2015;49(1):9-16.

Drug Information Association. *DIA Considerations Guide to Implementing Patient-Centric Initiatives in Health Care Product Development*. Drug Information Association. 2017.

Drug Information Association. *Capturing the Value of Patient Engagement: Summary of Results of the 2016 Study of Patient-Centric Initiatives in Drug Development*. Drug Information Association. 2017.

Duke Clinical Research Institute. Stakeholder Engagement Principles. Accessed February 17, 2021. <https://dcri.org/stakeholder-engagement/>

Eisenstein EL, Getz K, Harker M, et al. Framework for Aligning Research Sponsors and Patient Groups on Methods for Engagement. ISPOR Annual Meeting, 2016. Washington, DC. Clinical Trials Transformation Initiative (CTTI).

Gelijns AC, Gabriel SE. Looking beyond translation—integrating clinical research with medical practice. *N Engl J Med*. 2012;366(18):1659-1661.

Guisse JM, O'Haire C, McPheeters M, et al. A practice-based tool for engaging stakeholders in future research: a synthesis of current practices. *J Clin Epidemiol*. 2013;66(6):666-674.

- Hamilton CB, Hoens AM, Backman CL, et al. An empirically based conceptual framework for fostering meaningful patient engagement in research. *Health Expect*. 2018;21(1):396-406.
- Haywood K, A. Lyddiatt A, Brace-McDonnell SJ, Staniszewska S, Salek S. Establishing the values for patient engagement (PE) in health-related quality of life (HRQoL) research: an international, multiple-stakeholder perspective. *Qual Life Res*. 2017;26(6):1393-1404.
- Hoos A, Anderson J, Boutin M, et al. Partnering with patients in the development and lifecycle of medicines: a call for action. *Ther Innov Regul Sci*. 2015;49(6):929-939.
- Huang G, Bull J, McKee KJ, et al. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. *Contemp Clin Trials*. 2018;66:74-79.
- Levitan B, Getz K, Eisenstein EL, et al. Assessing the financial value of patient engagement. *Ther Innov Regul Sci*. 2018;52(2):220-229.
- Medical Device Innovation Consortium (MDIC). *Patient Engagement in Clinical Trials Survey Report*. 2019.
- Milken Institute (FasterCures). *Advancing Models of Patient Engagement: Patient Organizations as Research and Data Partners*. 2020.
- National Health Council. NHC Dialogue/Advancing Meaningful Patient Engagement in Research Development, and Review of Drugs. National Health Council & Genetic Alliance. 2015.
- National Health Council. *Integrating the Patient into the Drug Development Process: Developing FDA Guidance*. National Health Council & Genetic Alliance. 2016.
- National Health Council. *Tackling Representativeness: a Roadmap and Rubric*. National Health Council. 2017.
- National Health Council. *Patient Engagement Toolbox*. National Health Council. 2020.
- Perry B, Dombeck C, Smalley JB, et al. Development and Application of a Patient Group Engagement Prioritization Tool for Use in Medical Product Development. Preprints 2020, 2020070036.
- Patient Focused Medicine. *Collaborative Patient Engagement: Mapping the Global Landscape*. Patient Focused Medicine. 2016.
- Sheridan S, Schrandt S, Forsythe L, et al. The PCORI engagement rubric: promising practices for partnering in research. *Ann Fam Med*. 2017;15(2):165-170.
- Shippee ND, Domecq Garces JP, Prutsky Lopez GJ, et al. Patient and service user engagement in research: a systematic review and synthesized framework. *Health Expect*. 2015;18(5):1151-1166.
- Smith SK, Selig W, Harker M, et al. Patient engagement practices in clinical research among patient groups, industry, and academia in the United States: a survey. *PLoS One*. 2015;10(10):e0140232.

Spencer D, Handelin B, Basile RA, et al. (2016). Integrating rare disease patients into pre-clinical therapy development; finding our way with patient input. BioPontis Alliance for Rare Diseases. 2016.

Stergiopoulos S, Michaels DL, Kunz BL, Getz KA. Measuring the impact of patient engagement and patient centricity in clinical research and development. *Ther Innov Regul Sci*. 2020;54(1):103-116.

The Economist Intelligence Unit. *The Innovation Imperative: The Future of Drug Development*. Parts I and II. 2018;24(5):1033-1041.

5.4 Patient Preference in Clinical Trial Design

BIO Whitepaper. *Key Considerations in Integrating Patient Preferences in Drug Development*. 2016. Extensive Reference List.

Chaudhuri SE, Ho MP, Irony T, Sheldon M, Lo AW. Patient-centered clinical trials. *Drug Discov Today*. 2018;23(2):395-401.

Ho M, Saha A, McCleary KK, et al. A framework for incorporating patient preferences regarding benefits and risks into regulatory assessment of medical technologies. *Value Health*. 2016;19(6):746-750.

Irony T, Ho M, Christopher S, Levitan B. Incorporating patient preferences into medical device benefit-risk assessments. *Stat Biopharm Res*. 2016;8(3):230-236.

Isakov L, Lo AW, Montazerhodjat V. Is the FDA too conservative or too aggressive: a Bayesian decision analysis of clinical trial design. *Econom J*. 2019;211(1):117-136.

van Overbeeke E, Whichello C, Janssens R, et al. Factors and situations influencing the value of patient preference studies along the medical product lifecycle: a literature review. *Drug Discov Today*. 2019;24(1):57-68.

van Overbeeke E, Janssens R, Whichello C, et al. Design, conduct, and use of patient preference studies in the medical product life cycle: a multi-method study. *Front Pharmacol*. 2019;10:1395.



Contact Information

For more information, please contact
Liliana Rincon-Gonzalez, PhD, Program Director,
Science of Patient Input, at spi@mdic.org